Table 2.
Baseline characteristics of the overall cohort and stratified by the appropriateness of DOAC dosing.
| Patient Demographics | Appropriate Dose (n=7303) | Inappropriate Low Dose (n=1071) | Inappropriate High Dose (n=202) | P value |
|---|---|---|---|---|
| Age (years) | 69.0 ± 11.8 | 71.1± 11.9 | 79.0 ± 7.6 | <0.001 |
| Women | 2459 (33.7%) | 415 (38.7%) | 134 (66.3%) | <0.001 |
| Body Mass Index(kg/m2) | 30.5 ± 6.8 | 30.3 ± 6.6 | 25.5 ± 5.1 | <0.001 |
| Charlson co-morbidity Index, median (range) | 2 (0–23) | 3 (0–24) | 3 (0–15) | <0.001 |
| CHA2DS2-VASc score | 2.9 ± 1.8 | 3.5 ± 3.3 | 3.6 ± 3.3 | <0.001 |
| Creatinine (mg/dl) | 1.1 ± 0.4 | 1.1 ± 0.5 | 1.4 ± 0.9 | <0.001 |
| Creatinine Clearance (ml/min) |
86.7 ± 37.4 | 79.8 ± 40.4 | 40.2 ± 8.4 | <0.001 |
| Diabetes Mellitus | 1725 (23.6%) | 328 (30.6%) | 38 (18.8%) | <0.001 |
| Hypertension | 4909 (67.2%) | 768 (71.7%) | 134 (66.3%) | 0.01 |
| Hyperlipidemia | 3916 (53.6%) | 615 (57.4%) | 102 (50.5%) | 0.04 |
| Heart Failure | 2339 (32.0%) | 385 (35.9%) | 77 (38.1%) | 0.01 |
| Myocardial infarction | 833 (11.4%) | 165 (15.4%) | 28 (13.9%) | 0.0006 |
| Peripheral vascular disease | 651 (8.9%) | 114 (10.6%) | 22 (10.9%) | 0.12 |
| Aortic Atherosclerotic Disease | 626 (8.6%) | 109 (10.2%) | 14 (6.9%) | 0.15 |
| Liver Disease | 820 (11.2%) | 159 (14.8%) | 24 (11.9%) | 0.003 |
| Anemia | 832 (11.4%) | 188 (17.6%) | 31 (15.3%) | <0.001 |
| Alcoholism | 312 (4.3%) | 63 (5.9%) | 8 (4.0%) | 0.06 |
*
Mean ± SD unless otherwise specified